With the concerted support of 17 departments, the latest policies for the biopharmaceutical industry in the Jiangsu Pilot Free Trade Zone have been unveiled!
Release time:
2025-03-01
Recently, the “Policy Measures for Coordinated Support from Relevant Provincial Departments for the Open and Innovative Development of the Biopharmaceutical Industry in the China (Jiangsu) Pilot Free Trade Zone” (hereinafter referred to as the “Policy Measures”) were officially released!
Recently, the “Policy Measures for Coordinated Support from Relevant Provincial Departments for the Open and Innovative Development of the Biopharmaceutical Industry in the China (Jiangsu) Pilot Free Trade Zone” (hereinafter referred to as the “Policy Measures”) were officially released!
The biopharmaceutical industry is a shared competitive advantage across the three functional zones of the Jiangsu Pilot Free Trade Zone. The Nanjing zone is accelerating the development of “Gene City,” the Suzhou zone ranks first nationwide in biopharmaceutical industry competitiveness, and the Lianyungang zone leads the nation in biopharmaceutical innovation output. The Policy Measures focus on the biopharmaceutical industry—this common strength that the three zones are prioritizing—and seek to strengthen systemic integration, coordinated collaboration, and open innovation, with the aim of swiftly establishing the Jiangsu Pilot Free Trade Zone as a nationally leading and internationally recognized hub for biopharmaceutical innovation, a pioneering demonstration zone for institutional openness, and a model for high-quality industrial development.
Related News
Overview of Bioanalytical Methods for Cell Therapy Products
Cell and gene therapy (CGT) can be broadly classified, based on product format, into ex vivo gene therapy and in vivo gene therapy.
2026-04-03
With the rapid development of cell and gene therapy (CGT), dozens of CGT products have now been approved for market launch worldwide.
2026-04-03
During the third week of February 2025, the pharmaceutical and biotechnology sector continued to exhibit structural divergence. Over the week, the pharmaceutical and biotechnology index rose by 1.88%, outperforming both the CSI 300 Index and the Shanghai Composite Index, ranking ninth in terms of sector performance.
2025-03-01
Recently, the pharmaceutical and biotechnology sector has exhibited a pronounced structural market trend, driven by the deep integration of AI technologies with healthcare applications, which is spurring industry upgrades. At the same time, policy support for innovative drugs continues to strengthen, creating multiple favorable factors for the sector.
2025-03-01
Recently, the “Policy Measures for Coordinated Support from Relevant Provincial Departments for the Open and Innovative Development of the Biopharmaceutical Industry in the China (Jiangsu) Pilot Free Trade Zone” (hereinafter referred to as the “Policy Measures”) were officially released!
2025-03-01
Recently, the “Medical Device Blue Book: Report on the Development of China’s Medical Device Industry (2018),” jointly released in Beijing by the China Association for Pharmaceutical Regulatory Research and the Social Sciences Academic Press, stated that since the Belt and Road Initiative was proposed in 2013, demand for Chinese medical device products has increased among countries along the Belt and Road.
2025-03-01
Share
Wenzhou Kangrui Bio-Technology Co., Ltd.
Wenzhou KanryBio Biotech Co., Ltd.
Address: No. 1 Jinlian Road, Longwan District, Wenzhou City, Zhejiang Province
Email:BD@kanrybio.com
Phone:0512-66026888
Postal Code: 325000